185 related articles for article (PubMed ID: 26507307)
1. Counterpoint: the treatment decision design.
Brookhart MA
Am J Epidemiol; 2015 Nov; 182(10):840-5. PubMed ID: 26507307
[TBL] [Abstract][Full Text] [Related]
2. The limitations of observation studies for decision making regarding drugs efficacy and safety.
Gueyffier F; Cucherat M
Therapie; 2019 Apr; 74(2):181-185. PubMed ID: 30514576
[TBL] [Abstract][Full Text] [Related]
3. Medication safety research by observational study design.
Lao KS; Chui CS; Man KK; Lau WC; Chan EW; Wong IC
Int J Clin Pharm; 2016 Jun; 38(3):676-84. PubMed ID: 27003827
[TBL] [Abstract][Full Text] [Related]
4. What is pharmacoepidemiology? Definition, methods, interest and clinical applications.
Montastruc JL; Benevent J; Montastruc F; Bagheri H; Despas F; Lapeyre-Mestre M; Sommet A
Therapie; 2019 Apr; 74(2):169-174. PubMed ID: 30389102
[TBL] [Abstract][Full Text] [Related]
5. Counterpoint: epidemiology to guide decision-making: moving away from practice-free research.
Hernán MA
Am J Epidemiol; 2015 Nov; 182(10):834-9. PubMed ID: 26507306
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoepidemiology I: a review of pharmacoepidemiologic study designs.
Etminan M; Samii A
Pharmacotherapy; 2004 Aug; 24(8):964-9. PubMed ID: 15338844
[TBL] [Abstract][Full Text] [Related]
7. Expanding the Evidence Base: Comparing Randomized Controlled Trials and Observational Studies of Statins.
Atar D; Ong S; Lansberg PJ
Am J Ther; 2015; 22(5):e141-50. PubMed ID: 22487773
[TBL] [Abstract][Full Text] [Related]
8. Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficient.
Roberts AW; Dusetzina SB; Farley JF
J Comp Eff Res; 2015 Jan; 4(1):27-35. PubMed ID: 25565067
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision-making.
Caparrotta TM; Dear JW; Colhoun HM; Webb DJ
Br J Clin Pharmacol; 2019 Sep; 85(9):1907-1924. PubMed ID: 31206748
[TBL] [Abstract][Full Text] [Related]
10. Study designs in paediatric pharmacoepidemiology.
Verhamme K; Sturkenboom M
Eur J Clin Pharmacol; 2011 May; 67 Suppl 1():67-74. PubMed ID: 21107830
[TBL] [Abstract][Full Text] [Related]
11. Methods for time-varying exposure related problems in pharmacoepidemiology: An overview.
Pazzagli L; Linder M; Zhang M; Vago E; Stang P; Myers D; Andersen M; Bahmanyar S
Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):148-160. PubMed ID: 29285840
[TBL] [Abstract][Full Text] [Related]
12. Effects of expanding the look-back period to all available data in the assessment of covariates.
Nakasian SS; Rassen JA; Franklin JM
Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):890-899. PubMed ID: 28397352
[TBL] [Abstract][Full Text] [Related]
13. Update on clinical trials for the prevention of acute kidney injury in patients undergoing cardiac surgery.
Alsabbagh MM; Asmar A; Ejaz NI; Aiyer RK; Kambhampati G; Ejaz AA
Am J Surg; 2013 Jul; 206(1):86-95. PubMed ID: 23411349
[TBL] [Abstract][Full Text] [Related]
14. Understanding and Avoiding Immortal-Time Bias in Gastrointestinal Observational Research.
Targownik LE; Suissa S
Am J Gastroenterol; 2015 Dec; 110(12):1647-50. PubMed ID: 26323186
[TBL] [Abstract][Full Text] [Related]
15. Invited Commentary: The Prevalent New-User Design in Pharmacoepidemiology-Challenges and Opportunities.
Filion KB; Yu YH
Am J Epidemiol; 2021 Jul; 190(7):1349-1352. PubMed ID: 33350439
[TBL] [Abstract][Full Text] [Related]
16. Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making.
Etminan M; Gill S; Fitzgerald M; Samii A
J Clin Pharmacol; 2006 Jan; 46(1):6-9. PubMed ID: 16397278
[TBL] [Abstract][Full Text] [Related]
17. An application of propensity score matching using claims data.
Seeger JD; Williams PL; Walker AM
Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):465-76. PubMed ID: 15651087
[TBL] [Abstract][Full Text] [Related]
18. Active-comparator design and new-user design in observational studies.
Yoshida K; Solomon DH; Kim SC
Nat Rev Rheumatol; 2015 Jul; 11(7):437-41. PubMed ID: 25800216
[TBL] [Abstract][Full Text] [Related]
19. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins.
García Rodríguez LA; Herings R; Johansson S
Pharmacoepidemiol Drug Saf; 2010 Dec; 19(12):1218-24. PubMed ID: 20922707
[TBL] [Abstract][Full Text] [Related]
20. Implementing a decision-theoretic design in clinical trials: why and how?
Palmer CR; Shahumyan H
Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
